{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-005768","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.320377+00:00","generated_at":"2026-05-21T05:17:21.929177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences Q1 net loss $1.0M; pivots to metabolic disease diagnostics, plans FDA de novo trial","bullets":["Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.","Cash burn improved to $1.2M in Q1 2025 from $1.7M in Q1 2024; cash at April 30 was $2.5M after $0.8M ATM raise.","Strategic pivot to point-of-care liver fat diagnostics for metabolic disease; redesigned TAEUS system with AI.","Revised FDA regulatory strategy: plans prospective multicenter trial of ~250 subjects for De Novo submission.","Two new patents issued in China, bringing IP portfolio to 84 total."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-005768","json":"https://secwatch.observer/filing/0001654954-25-005768.json","markdown":"https://secwatch.observer/filing/0001654954-25-005768.md","text":"https://secwatch.observer/filing/0001654954-25-005768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/0001654954-25-005768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:17:21.929177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}